On December 16, 2014, the U.S. Department of Homeland
Security (DHS) released a public request for information (RFI) seeking
technologies relevant to the automated detection and identification of
air-borne biological agents. This release sparks movement for DHS’s efforts to
drastically improve the BioWatch Program, which has been slumbering for the
past two years. The BioWatch Program was established in 2003, as a means to
address the ever-increasing threat of bioterrorism. BioWatch’s goal, according
to the DHS is, “to detect the presence of biological agents of concern in a
timely manner and identify the target agents with a high degree of confidence.”
Biological Threats
In 2001, on the heels of the 9/11 terror attacks, the public
became aware of bio-terrorism after several cases of inhalation anthrax were
reported. Twenty-two people became ill after envelopes filled with a white
powder containing anthrax spores were mailed to two U.S. Senators. Five of the
22 who came in contact with the envelopes died. While there have been no
reports of inhalation anthrax being used as a bio-terrorism agent since 2001,
the threat remains strong. The Centers for Disease Control (CDC), rates anthrax
as a “Tier 1” threat, meaning its biological agents and toxins present the highest
risk for deliberate misuse, possessing the ability to yield mass casualties,
cripple the economy and infrastructure, diminish public morale, and cause a
severe threat to public health and safety. Anthrax is one of over 40 agents the
CDC has on its bio-terrorism watch list.
Advancements in Bio-Detection
DHS is primed to release the next generation of BioWatch,
bolstered by the latest and greatest technological advancements in the field of
biodetection. The recently released RFI calls for a “cost-effective autonomous
biological detection solution.” Necessary capabilities include speed, fully
autonomous operation, a high level of accuracy, and consistent identification
and preservation of multiple biological agents. One corporation who has managed
to check off all of DHS’ must-haves for the new face of BioWatch is PositiveID
(OTCQB: PSID).
Introducing M-BAND
PositiveID Corporation’s M-BAND (Microfluidic Bio-agent
Autonomous Networked Detector) is a state-of-the-art, fully automated airborne
pathogen detection system. Roughly the size of an a/c unit, it can be installed
in transportation facilities, arenas, malls, stadiums, amusement parks, office
buildings and more. The product of $30 million in funding provided by DHS,
M-BAND is currently being field-tested by the Department of Defense (DOD) in
South Korea and on military bases in the States. Having a working rapport with
the DOD and building from DHS’ funding, PositiveID’s M-BAND sits pretty as an
ideal candidate for the next generation of BioWatch. Here are some of its
distinguishing features:
M-BAND
operates autonomously on a 30-day cycle.
provides results in 3 to 6 hours.
all data transmissions are sent via a secure wireless
network to an off-site monitoring facility in real time.
able to detect multiple organisms and toxins simultaneously.
analyzes and stores samples for up to 30 days.
Current DHS BioWatch equipment requires manual, daily
monitoring. A technician is sent into the field to retrieve air filters that
are then sent to a laboratory for analysis – a 36 to 48 hour process.
M-BAND’s point-of-need capabilities will revolutionize the
field of bio-detection and aid the DHS in providing timely, cost-effective and
life-saving monitoring and security.
Viability
In March 2014, PositiveID joined forces with United
Technologies Aerospace Systems (UTAS), to provide M-BAND units for the DOD’s
JUPITR Program. The Joint United States Forces Korea Portal and Integrated
Threat Recognition (JUPITR) Program is currently testing M-BAND’s prospective
capabilities in aiding U.S. Armed Forces. The JUPITR contract is predicted to
net PositiveID $1 million in 2014-15 alone. The U.S. government’s next
generation BioWatch Program contract has been predicted to be worth between
$3-5 billion. PositiveID has previously announced that they have an exclusive
teaming and licensing agreement in place with The Boeing Company related to
BioWatch. With M-BAND systems already being operated and tested by the military
and only one other model available that potentially meets BioWatch’s RFI
requirements, PositiveID is in a great position to secure the deal.
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment